166 related articles for article (PubMed ID: 33322500)
21. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
22. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
[TBL] [Abstract][Full Text] [Related]
23. HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy.
Faaborg L; Jakobsen A; Waldstrøm M; Petersen CB; Andersen RF; Steffensen KD
Biomark Med; 2021 Oct; 15(15):1309-1317. PubMed ID: 34514844
[No Abstract] [Full Text] [Related]
24. Identification of a Clinical Cutoff Value for Multiplex KRAS
Lee KH; Lee TH; Choi MK; Kwon IS; Bae GE; Yeo MK
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708359
[TBL] [Abstract][Full Text] [Related]
25. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
Taly V; Pekin D; Benhaim L; Kotsopoulos SK; Le Corre D; Li X; Atochin I; Link DR; Griffiths AD; Pallier K; Blons H; Bouché O; Landi B; Hutchison JB; Laurent-Puig P
Clin Chem; 2013 Dec; 59(12):1722-31. PubMed ID: 23938455
[TBL] [Abstract][Full Text] [Related]
26. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer.
Wen SWC; Andersen RF; Hansen TF; Nyhus CH; Hager H; Hilberg O; Jakobsen A
Transl Lung Cancer Res; 2021 Feb; 10(2):855-865. PubMed ID: 33718027
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.
Guibert N; Mazieres J; Delaunay M; Casanova A; Farella M; Keller L; Favre G; Pradines A
Oncotarget; 2017 Jun; 8(23):38056-38060. PubMed ID: 28445137
[TBL] [Abstract][Full Text] [Related]
28. Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.
Taus Á; Camacho L; Rocha P; Hernández A; Longarón R; Clavé S; Fernández-Ibarrondo L; Salido M; Hardy-Werbin M; Fernández-Rodríguez C; Albanell J; Bellosillo B; Arriola E
Arch Bronconeumol (Engl Ed); 2021 May; 57(5):323-329. PubMed ID: 32253118
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
30. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
31. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
32. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
33. Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
Pender A; Garcia-Murillas I; Rana S; Cutts RJ; Kelly G; Fenwick K; Kozarewa I; Gonzalez de Castro D; Bhosle J; O'Brien M; Turner NC; Popat S; Downward J
PLoS One; 2015; 10(9):e0139074. PubMed ID: 26413866
[TBL] [Abstract][Full Text] [Related]
34. Detection of
Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
[TBL] [Abstract][Full Text] [Related]
35. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
36. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
37. Concordance of Genomic Profiles in Matched Tissue and Plasma Samples From Chinese Patients With Lung Cancer.
He Y; Guo W; Xu M; Huang J; Zhang X; Su H; Hong D; Liu Q
Clin Med Insights Oncol; 2022; 16():11795549221116834. PubMed ID: 36310733
[TBL] [Abstract][Full Text] [Related]
38. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
39. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
40. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
